摘要
紫癜性肾炎（HSPN）是儿童期最常见的继发性肾小球肾炎，尽管大部分患者预后良好，但仍也有少数患者可进展为终末期。肾病，因此，探讨HSPN的综合治疗方案对改善患儿的预后具有重要的临床意义。现主要分析国内外近年来HSPN的综合治疗进展，包括糖皮质激素、免疫抑制剂（环磷酰胺、霉酚酸酯、环孢素／他克莫司、咪唑立宾、雷公藤总苷）、血管紧张素转化酶抑制剂／血管紧张素受体拮抗剂、扁桃体切除、血浆置换等措施的临床疗效及不良反应，为临床HSPN患者的治疗提供依据和帮助。
Henoch-Schonlein purpura （HSP） is one of the most common vasculitides in children with many manifestations including skin purpura, arthritis, abdominal pain and renal involvement. The renal involvement（ HenochSehtinlein purpura nephritis, HSPN） is the principal cause of morbidity and major risk factor for prognosis in HSP. The paper reviewed the updated treatment strategy for HSPN. Accordingly, steroids, cyclophosphamide, mycophenolate mofetil, mizoribine, cyelosporine, triptolide, angiotensin converting enzyme inhibitors （ ACEI ） / angiotensin receptor blockers（ARB）, plasma apheresis and tonsillectomy are possible indicator for the further therapy of HSPN. Furthermore, prospective randomized controlled treatment studies on children with severe HSPN would be needed
出处
《中华实用儿科临床杂志》
CAS
CSCD
北大核心
2014年第17期1287-1290,共4页
Chinese Journal of Applied Clinical Pediatrics
关键词
儿童
紫癜性肾炎
综合治疗
免疫抑制剂
Child
Henoch-schonlein purpura nephritis
Combined therapy
Immunosuppressive agents
